Compounded GLP-1 medications and FDA policy in 2026
The most important point is simple: a compounded preparation is not FDA-approved and not brand-identical. Its possible use depends on an individual need, a valid prescription, applicable law, and a pharmacy able to dispense it legally.
What changed after the shortages
FDA determined that the tirzepatide injection shortage was resolved in December 2024 and that the semaglutide injection shortage was resolved in February 2025. That ended temporary shortage-based flexibility. It did not make every later prescription automatically permitted or prohibited.
In 2026 FDA again reminded compounders that the conditions of section 503A or 503B must be met. For a 503A preparation, the prescription is tied to an identified patient. Restrictions on copies of commercially available drugs and any significant difference require patient-specific analysis.
What a compounded preparation is not
It is not an approved generic, is not interchangeable with Wegovy, Ozempic, Mounjaro, or Zepbound, and does not inherit those products' trial results. Brand evidence describes the product and formulation that were studied.
Hold us to this standard
Every check on this page is one you can run on New Hope
Care starts with a $119 review of your history and contraindications by Dr. Anjmun Sharma, MD. If a prescription is appropriate, we name the dispensing pharmacy so you can verify its license before fulfillment, and we say plainly that compounded semaglutide is not FDA-approved, not brand-identical, and that results vary.
See if you are a candidate, free 2-minute quizSeparate, verifiable roles
Dr. Anjmun Sharma, MD reviews history, contraindications, current medications, and clinical need. If a preparation is prescribed and can be filled legally for the patient's location, the licensed pharmacy prepares and dispenses it.
Useful questions for the visit
- Is an available approved drug able to meet my need?
- What individual medical need supports the recommendation?
- Which pharmacy would dispense, and where can I verify its license?
- What does the evaluation include, and what is billed separately?
- How would regulatory or availability changes be communicated?
Current primary sources
Confirm location and eligibility
Care, prescribing, and dispensing depend on location, medical evaluation, and pharmacy coverage.
Check availabilityFrequently asked questions
Does FDA approve compounded semaglutide or tirzepatide?
No. FDA does not review or approve the finished compounded preparation for safety, effectiveness, or quality before marketing. It is not brand-identical, and results vary by individual.
Did the end of the shortage prohibit every 503A prescription?
There is no one-size-fits-all answer. The shortage resolution ended shortage-based flexibility, while section 503A has separate conditions and limits that must be evaluated for each patient and prescription.
Who prepares and dispenses the medication?
If a compounded prescription is issued and can be filled legally, the licensed pharmacy prepares and dispenses it. The clinic evaluates and prescribes when appropriate but does not manufacture or dispense.
Is cost preference enough to establish a significant difference?
It should not be treated as an automatic justification. When the significant-difference exception is relied on, the prescriber determines and documents the individual patient's need.
What does the evaluation cost?
If care is available for your location, the medical evaluation is $119. Medication is priced separately, and a prescription is not guaranteed.
This article is educational and does not replace an individual medical evaluation. Do not start, stop, or change a medication without speaking with your health care professional.